OvaCure - Innovation in Ovarian Cancer Research
OvaCure is happy to report improved survival rates for women with ovarian cancer!
A huge thank you to OvaCure principal investigator, Professor Lana Kandalaft and her team for their important work in developing the best vaccine approach as a treatment for ovarian cancer.
OvaCure is pleased to announce our new non-profit US organisation status as a 501(c)3 tax exempt charity!
The OvaCure Foundation will function as our new US entity which will bridge our work across the pond.
OvaCure is excited to participate in this year's ASCO
June 1-5, 2018
McCormick Place - Chicago, IL
We will meet our project Personal Investigators and new Key External Experts at ASCO 2018.
OvaCure is proud to support the UN Sustainable Development Goals #3 #5 and #17.
OvaCure strives to better global health and well being, gender equality and partner with others to cure ovarian cancer.